Sanofi $SNY Shares Sold by Integrated Wealth Concepts LLC

Integrated Wealth Concepts LLC cut its stake in Sanofi (NASDAQ:SNY) by 10.0% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,709 shares of the company’s stock after selling 1,635 shares during the period. Integrated Wealth Concepts LLC’s holdings in Sanofi were worth $816,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Accent Capital Management LLC acquired a new stake in Sanofi in the first quarter valued at $29,000. Eastern Bank raised its position in shares of Sanofi by 121.0% during the 1st quarter. Eastern Bank now owns 548 shares of the company’s stock valued at $30,000 after acquiring an additional 300 shares in the last quarter. Banque Transatlantique SA acquired a new stake in shares of Sanofi during the 1st quarter valued at approximately $33,000. Golden State Wealth Management LLC raised its position in shares of Sanofi by 619.3% during the 1st quarter. Golden State Wealth Management LLC now owns 633 shares of the company’s stock valued at $35,000 after acquiring an additional 545 shares in the last quarter. Finally, Brentview Investment Management LLC acquired a new stake in shares of Sanofi during the 1st quarter valued at approximately $42,000. 14.04% of the stock is owned by institutional investors and hedge funds.

Sanofi Trading Up 1.0%

NASDAQ:SNY opened at $47.65 on Friday. Sanofi has a 1 year low of $44.73 and a 1 year high of $60.12. The stock has a market cap of $117.01 billion, a price-to-earnings ratio of 11.45, a PEG ratio of 1.12 and a beta of 0.51. The business has a fifty day moving average of $48.68 and a 200-day moving average of $51.21. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.94 and a current ratio of 1.27.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Thursday, July 31st. The company reported $0.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.96 by ($0.06). Sanofi had a return on equity of 16.86% and a net margin of 21.47%.The business had revenue of $11.34 billion during the quarter, compared to the consensus estimate of $9.91 billion. During the same period in the previous year, the company posted $1.73 EPS. The company’s revenue for the quarter was down 7.0% compared to the same quarter last year. Equities analysts predict that Sanofi will post 4.36 earnings per share for the current year.

Wall Street Analysts Forecast Growth

SNY has been the topic of several research reports. Morgan Stanley raised Sanofi from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $56.00 to $58.00 in a research report on Monday. Barclays reissued an “overweight” rating on shares of Sanofi in a research report on Wednesday, July 2nd. JPMorgan Chase & Co. raised Sanofi from a “neutral” rating to an “overweight” rating in a research report on Friday, August 8th. Wall Street Zen upgraded Sanofi from a “hold” rating to a “buy” rating in a research note on Saturday, August 2nd. Finally, Guggenheim restated a “buy” rating on shares of Sanofi in a research note on Tuesday, June 3rd. Three equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $62.67.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.